The Perennial Allergic Rhinitis drugs in development market research report provides comprehensive information on the therapeutics under development for Perennial Allergic Rhinitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Perennial Allergic Rhinitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Perennial Allergic Rhinitis and features dormant and discontinued products.
GlobalData tracks 12 drugs in development for Perennial Allergic Rhinitis by 12 companies/universities/institutes. The top development phase for Perennial Allergic Rhinitis is phase ii with five drugs in that stage. The Perennial Allergic Rhinitis pipeline has ten drugs in development by companies and two by universities/ institutes. Some of the companies in the Perennial Allergic Rhinitis pipeline products market are: Daewon Pharmaceutical, Faes Farma and Ache Laboratorios Farmaceuticos.
The key targets in the Perennial Allergic Rhinitis pipeline products market include Interleukin 13, Histamine Receptor, and Histamine.
The key mechanisms of action in the Perennial Allergic Rhinitis pipeline product include Histamine Receptor Antagonist with one drug in Discovery. The Perennial Allergic Rhinitis pipeline products include six routes of administration with the top ROA being Oral and four key molecule types in the Perennial Allergic Rhinitis pipeline products market including Allergenics (Allergen), and Small Molecule.
Perennial Allergic Rhinitis overview
Perennial rhinitis is an inflammatory condition that causes nasal congestion and runny nose. It is of two types: perennial allergic rhinitis and non-allergic rhinitis. Dust mites, pet dander, and mold are the most common allergens respoinsible for allergic rhinitis. Physical examination, blood or skin testing, and CT scan can be used for diagnosis. Management includes allergen avoidance along with pharmacological treatment. Corticosteroids, antihistamines, decongestants, anti-inflammatories, and allergen desensitization are treatment options.
For a complete picture of Perennial Allergic Rhinitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
